Načítá se...
An economic evaluation of trastuzumab as adjuvant treatment of early HER2-positive breast cancer patients in Colombia
Objective: Trastuzumab (Herceptin®), a recombinant, humanized, monoclonal antibody targeting HER2 is well established as an effective treatment for HER2-positive breast cancer. Evidence from developed countries showed that trastuzumab was cost-effective; but there are few evidences in developing cou...
Uloženo v:
| Vydáno v: | Biomédica |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Instituto Nacional de Salud
2013
|
| Témata: | |
| On-line přístup: | https://www.redalyc.org/articulo.oa?id=84329151010 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|